OBJECTIVES: To determine if serum procalcitonin, an indicator of bacterial etiology in pneumonia in all ages and a predictor of severe pneumonia in adults, is associated with disease severity in children with community-acquired pneumonia. METHODS: We prospectively enrolled children 2 months to <18 years with clinical and radiographic pneumonia at 2 children's hospitals (2014-2019). Procalcitonin samples were obtained at presentation. An ordinal outcome scale of pneumonia severity was defined: very severe (intubation, shock, or death), severe (intensive care admission without very severe features and/or high-flow nasal cannula), moderate (hospitalization without severe or very severe features), and mild (discharge). Hospital length of stay (LOS) was also examined. Ordinal logistic regression was used to model associations between procalcitonin and outcomes. We estimated adjusted odds ratios (aORs) for a variety of cut points of procalcitonin ranging from 0.25 to 3.5 ng/mL. RESULTS: The study included 488 children with pneumonia; 30 (6%) were classified as very severe, 106 (22%) as severe, 327 (67%) as moderate, and 25 (5%) as mild. Median procalcitonin in the very severe group was 5.06 (interquartile range [IQR] 0.90-16.83), 0.38 (IQR 0.11-2.11) in the severe group, 0.29 (IQR 0.09-1.90) in the moderate group, and 0.21 (IQR 0.12-1.2) in the mild group. Increasing procalcitonin was associated with increasing severity (range of aORs: 1.03-1.25) and increased LOS (range of aORs: 1.04-1.36). All comparisons were statistically significant. CONCLUSIONS: Higher procalcitonin was associated with increased severity and LOS. Procalcitonin may be useful in helping clinicians evaluate pneumonia severity.
OBJECTIVES: To determine if serum procalcitonin, an indicator of bacterial etiology in pneumonia in all ages and a predictor of severe pneumonia in adults, is associated with disease severity in children with community-acquired pneumonia. METHODS: We prospectively enrolled children 2 months to <18 years with clinical and radiographic pneumonia at 2 children's hospitals (2014-2019). Procalcitonin samples were obtained at presentation. An ordinal outcome scale of pneumonia severity was defined: very severe (intubation, shock, or death), severe (intensive care admission without very severe features and/or high-flow nasal cannula), moderate (hospitalization without severe or very severe features), and mild (discharge). Hospital length of stay (LOS) was also examined. Ordinal logistic regression was used to model associations between procalcitonin and outcomes. We estimated adjusted odds ratios (aORs) for a variety of cut points of procalcitonin ranging from 0.25 to 3.5 ng/mL. RESULTS: The study included 488 children with pneumonia; 30 (6%) were classified as very severe, 106 (22%) as severe, 327 (67%) as moderate, and 25 (5%) as mild. Median procalcitonin in the very severe group was 5.06 (interquartile range [IQR] 0.90-16.83), 0.38 (IQR 0.11-2.11) in the severe group, 0.29 (IQR 0.09-1.90) in the moderate group, and 0.21 (IQR 0.12-1.2) in the mild group. Increasing procalcitonin was associated with increasing severity (range of aORs: 1.03-1.25) and increased LOS (range of aORs: 1.04-1.36). All comparisons were statistically significant. CONCLUSIONS: Higher procalcitonin was associated with increased severity and LOS. Procalcitonin may be useful in helping clinicians evaluate pneumonia severity.
Authors: M J Fine; L J Hough; A R Medsger; Y H Li; E M Ricci; D E Singer; T J Marrie; C M Coley; M B Walsh; M Karpf; K C Lahive; W N Kapoor Journal: Arch Intern Med Date: 1997-01-13
Authors: Todd W Rice; Arthur P Wheeler; Gordon R Bernard; Douglas L Hayden; David A Schoenfeld; Lorraine B Ware Journal: Chest Date: 2007-06-15 Impact factor: 9.410
Authors: David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus Journal: Ann Emerg Med Date: 2008-03-17 Impact factor: 5.721
Authors: Ilija Andrijevic; Jovan Matijasevic; Ljiljana Andrijevic; Tomi Kovacevic; Bojan Zaric Journal: Ann Thorac Med Date: 2014-07 Impact factor: 2.219
Authors: Wesley H Self; Robert A Balk; Carlos G Grijalva; Derek J Williams; Yuwei Zhu; Evan J Anderson; Grant W Waterer; D Mark Courtney; Anna M Bramley; Christopher Trabue; Sherene Fakhran; Anne J Blaschke; Seema Jain; Kathryn M Edwards; Richard G Wunderink Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Sophie E Katz; Laura F Sartori; Andras Szeles; Rendie McHenry; J Eric Stanford; Meng Xu; Jennifer M Colby; Natasha Halasa; Derek J Williams; Ritu Banerjee Journal: Infect Dis Ther Date: 2019-06-29